In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) was $14.89 for the day, up 30.73% from the previous closing price of $11.39. In other words, the price has increased by $30.73 from its previous closing price. On the day, 1.81 million shares were traded. ARCT stock price reached its highest trading level at $15.5 during the session, while it also had its lowest trading level at $11.8725.
Ratios:
Our analysis of ARCT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.90 and its Current Ratio is at 5.90. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on May 28, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $32.
On January 28, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $41.
On August 12, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $70.Leerink Partners initiated its Outperform rating on August 12, 2024, with a $70 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 15 ’24 when Chivukula Pad sold 12,000 shares for $20.76 per share. The transaction valued at 249,121 led to the insider holds 435,334 shares of the business.
Chivukula Pad bought 12,000 shares of ARCT for $249,121 on Oct 15 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARCT now has a Market Capitalization of 404330528 and an Enterprise Value of 230699712. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.68 while its Price-to-Book (P/B) ratio in mrq is 1.75. Its current Enterprise Value per Revenue stands at 1.889 whereas that against EBITDA is -3.332.
Stock Price History:
The Beta on a monthly basis for ARCT is 2.37, which has changed by -0.2248829 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, ARCT has reached a high of $25.88, while it has fallen to a 52-week low of $8.04. The 50-Day Moving Average of the stock is 13.19%, while the 200-Day Moving Average is calculated to be 1.38%.
Shares Statistics:
ARCT traded an average of 481.54K shares per day over the past three months and 600490 shares per day over the past ten days. A total of 27.15M shares are outstanding, with a floating share count of 24.83M. Insiders hold about 8.44% of the company’s shares, while institutions hold 95.69% stake in the company. Shares short for ARCT as of 1753920000 were 4371328 with a Short Ratio of 9.08, compared to 1751241600 on 5039101. Therefore, it implies a Short% of Shares Outstanding of 4371328 and a Short% of Float of 24.94.
Earnings Estimates
Investors are keenly observing as 7.0 analysts analyze and rate the current performance of Arcturus Therapeutics Holdings Inc (ARCT) in the stock market.The consensus estimate for the next quarter is -$0.9, with high estimates of -$0.12 and low estimates of -$1.88.
Analysts are recommending an EPS of between -$1.04 and -$4.42 for the fiscal current year, implying an average EPS of -$2.84. EPS for the following year is -$2.05, with 7.0 analysts recommending between $1.41 and -$4.11.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for ARCT’s current fiscal year. The highest revenue estimate was $114.28M, while the lowest revenue estimate was $57.68M, resulting in an average revenue estimate of $87.12M. In the same quarter a year ago, actual revenue was $152.31MBased on 10 analysts’ estimates, the company’s revenue will be $108.62M in the next fiscal year. The high estimate is $279.39M and the low estimate is $14.63M.
